CoChat

Controlled Trial of High Doses of Pemoline for Adults With Attention-Deficit/Hyperactivity Disorder

Wilens, Timothy E., Biederman, Joseph, Spencer, Thomas J., Frazier, Jean, Prince, Jefferson, Bostic, Jeff, Rater, Michael, Soriano, Jennifer, Hatch, Mary, Sienna, Melissa, Millstein, Rachael B., Abrantes, Ana · 1999 · Journal of Clinical Psychopharmacology
Cited by 65

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Despite the increasing awareness of attention-deficit/hyperactivity disorder (ADHD) in adults, there are a limited number of controlled pharmacologic studies of this disorder. Because the stimulant medication magnesium pemoline (Cylert, Abbott Laboratories, Abbott Park, IL) has been found effective in treating ADHD in pediatric groups, we tested its efficacy in adults with ADHD using higher daily doses than those previously studied. We conducted a 10-week, double-blind, placebo-controlled, crossover design study of pemoline at a target daily dose of 3 mg/kg per day in 35 adult patients with DSM-III-R and -IV ADHD. We used standardized structured psychiatric instruments for diagnosis. To measure improvement, we used separate assessments of ADHD, depressive, and anxiety symptoms at baseline and at each biweekly visit. ADHD outcome was determined using the ADHD symptom checklist and Clinical Global Impression scales of Severity and Improvement. Of the 35 adults with ADHD who were randomized in the trial, 27 (77%) completed the protocol. Treatment with pemoline in the final week of the 4-week active phase was best tolerated at doses substantially lower than the target dose of 3 mg/kg per day (mean dose, 2.2 mg/kg per day; mean+/-SD, 148+/-95 mg). Pemoline was significantly better at reducing ADHD symptoms compared with placebo (z = 2.4,p < 0.02). Using a predefined 30% reduction in symptoms as an indication of improvement, 50% of pemoline-treated subjects and 17% of subjects in the placebo group were considered positive responders (chi2 = 7.1, p = 0.008). These results indicate that pemoline is moderately effective in the treatment of ADHD in adults. Although robust doses were targeted, most adults preferred more moderate dosing (120-160 mg/day). Given the limited efficacy, tolerability, and concerns of hepatic dysfunction, pemoline should be considered as second-line medication for treating ADHD in adults.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/00004714-199906000-00009

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 65

Metadata

Authors
Wilens, T. E., Biederman, J., Spencer, T. J., Frazier, J., Prince, J., Bostic, J., Rater, M., Soriano, J., Hatch, M., Sienna, M., Millstein, R. B., & Abrantes, A.
Venue
Journal of Clinical Psychopharmacology
Published
1999-06
Volume
19
Issue
3
Pages
257-264
ISSN
0271-0749 (ISSN-L)
OpenAlex
W1979465426
Cited by
65
References
8
FWCI
5.48
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Controlled Trial of High Doses of Pemoline for Adults With Attention-Deficit/Hyperactivity Disorder. https://app.cochat.ai/papers/10.1097/00004714-199906000-00009
The paper
Wilens, T. E., Biederman, J., Spencer, T. J., Frazier, J., Prince, J., Bostic, J., Rater, M., Soriano, J., Hatch, M., Sienna, M., Millstein, R. B., & Abrantes, A. (1999). Controlled Trial of High Doses of Pemoline for Adults With Attention-Deficit/Hyperactivity Disorder. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/00004714-199906000-00009

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.